Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950501 | PMC |
| http://dx.doi.org/10.1200/JCO.2012.43.2716 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Report from the 25th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Gastric and Gastroesophageal Cancers, Winnipeg, Manitoba, 26-27 October 2023.
Curr Oncol
October 2024
CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
The 25th Annual Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC) was held in Winnipeg, Manitoba, on 26-27 October 2023. The WCGCCC is an interactive multidisciplinary conference that was attended by healthcare professionals from across Western Canada (British Columbia, Alberta, and Manitoba) who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; oncology nurses; pharmacists; and a family physician in oncology (FPO) participated in presentation and discussion sessions for the purpose of developing the recommendations presented here.
View Article and Find Full Text PDFComprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies Identifies Variants That Can Alter Clinical Practice.
Hematol Rep
September 2024
Division of Hematologic Malignancies & Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC 27705, USA.
Article Synopsis
- Comprehensive genomic profiling (CGP) is commonly used to guide treatment for solid tumors and myeloid neoplasms, but its effectiveness for lymphoid and histiocytic cancers is less established.
- In a study of 105 CGP samples from patients with non-myeloid hematologic malignancies, 88% showed pathogenic mutations, with 72% of patients having mutations that could influence their treatment or prognosis.
- The study found that CGP led to a significant change in management for 22% of patients, particularly in cases where resistance variants were identified, affecting treatment decisions in nearly 70% of those cases.
Beyond HMAs: Novel Targets and Therapeutic Approaches.
Semin Hematol
December 2024
Department of Internal Medicine, Section of Hematology, Yale University and Yale Comprehensive Cancer Center, New Haven, Connecticut.
Article Synopsis
- * Treatment for lower-risk MDS focuses on improving quality of life and may include therapies like erythropoiesis-stimulating agents and new medications like imetelstat, while higher-risk MDS often utilizes hypomethylating agents as standard care, with ongoing research into combination therapies.
- * Despite advancements in treatment options, especially for higher-risk MDS, challenges remain due to limited effective therapies after initial treatment failures, highlighting the need for new drug developments that could change current treatment approaches.
The co-occurrence of germline and somatic oncogenic alterations is frequently observed in breast cancer, but their combined biologic and clinical significance has not been evaluated. To assess the role of germline-somatic interactions on outcomes in routine practice, we developed an integrated clinicogenomic pipeline to analyze the genomes of over 4,500 patients with breast cancer. We find that germline (g) -associated tumors are enriched for loss-of-function mutations and manifest poor outcomes on standard-of-care, front-line CDK4/6 inhibitor (CDK4/6i) combinations.
View Article and Find Full Text PDFBiomarker-directed therapy in multiple myeloma.
Curr Opin Oncol
November 2024
St Vincent's Hospital, University of Melbourne, Melbourne, Australia.
Purpose Of Review: Multiple myeloma is currently treated with a one-size-fits-all approach despite significant heterogeneity in patient outcomes and disease molecular constitution. A personalised approach would tailor therapy to unique patient or disease characteristics.
Recent Findings: Well established prognostic biomarkers such as cytogenetic risk and patient frailty status are being evaluated as potential predictive biomarkers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!